参考文献:Billingsle KL, Buchwald SL (2008) An improved system for the palladium-catalyzed borylation of aryl halides with pinacol borane. J Org Chem 14:5589鈥?591View Article Chen HM, Cui JR, Hoffman JE, Johnson MC, Kania RS, Le TQM, Nambu D, Pairish MA, Shen H, Tran-dube MB (2007) Triazolopyrazine derivatives useful as anti-cancer agents. W.O. Patent. 2007/132308 Colombo F, Tintori C, Furlan A, Borrelli S, Christodoulou MS, Dono R, Maina F, Botta M, Amat M, Bosch J, Passarella D (2012) 鈥楥lick鈥?synthesis of a triazole-based inhibitor of Met functions in cancer cells. Bioorg Med Chem Lett 22:4693鈥?696PubMed View Article Corso S, Comoglio PM, Giordano S (2005) Cancer therapy: can the challenge be MET? Trends Mol Med 6:284鈥?92View Article Cui JJ (2007) Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat 17:1035鈥?045View Article Cui JJ, McTigue M, Nambu M, Tran-Dub茅 M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, Jalaie M, Goetz GH, Ryan K, Grodsky N, Deng YL, Parker M, Timofeevski S, Murray BW, Yamazaki S, Aguirre S, Li Q, Zou H, Christensen J (2012) Discovery of a novel class of exquisitely selective mesenchymalepithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J Med Chem 55:8091鈥?109PubMed View Article Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547鈥?555PubMed View Article Furlan A, Colombo F, Kover A, Issaly N, Tintori C, Angeli L, Leroux V, Letard S, Amat M, Asses Y, Maigret B, Dubreuil P, Botta M, Dono R, Bosch J, Piccolo O, Passarella D, Maina F (2012) Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. Eur J Med Chem 47:239鈥?54PubMed View Article Gherardi E, Birchmeier WC, Birchmeier GVW (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2:89鈥?03View Article Hiroki N, Takashi C, Kenji M, Takaaki AF, Hiroshi S, Kwangseok K, Hiroshi K (2010) Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors. Bioorg Med Chem Lett 20:1405鈥?409View Article Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499鈥?11PubMed View Article Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21:281鈥?06PubMed View Article Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947鈥?953PubMed View Article Lu TB, Alexander R, Connors RW, Cummings MD, Galemmo RA, Hufnagel H R, Johnson DL, Khalil E, Leonard KA, Markotan TP, Maroney AC, Sechler JL, Trawins JM, Tuman RW (2007) Triazolopyridazines as tyrosine kinase modulators. W.O. Patent. 2007/075567 Ma PC, Kijim T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272鈥?281PubMed Ma PC, Jagadeesh S, Jagadeeswaran R, Fox EA, Christensen J, Maulik G, Naoki K, Lader A, Richards W, Sugarbaker D, Meyerson M, Salgia R (2004) c-MET expression/activation, functions, and mutations in non-small cell lung cancer. Proc Am Assoc Cancer Res 45:1875 Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hugson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68鈥?3PubMed View Article Underiner TL, Herbertz T, Miknyoczki SJ (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem 10:7鈥?7PubMed View Article Yang F, Praveena ST, Patrick CM (2012) Met signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2:459鈥?67 Ye LB, Tian YX, Li ZH, Jin H, Zhu ZG, Wan SH, Zhang JY, Yu PJ, Zhang JJ, Wu SG (2012a) Synthesis and molecular docking studies of some novel spiro[indoline-3,4鈥?piperidine]-2(1H)-ones as potential c-Met inhibitors. Eur J Med Chem 50:370鈥?75PubMed View Article Ye LB, Tian YX, Li ZH, Zhang JJ, Wu SG (2012b) Design and synthesis of some novel 2,3,4,5-tetrahydro-1H-pyrido[4, 3-b] indoles as potential c-Met inhibitors. Helv Chim Acta 95:320鈥?26View Article Ye LB, Ou XM, Tian YX, Yu BW, Luo Y, Feng BH, Lin HS, Zhang JJ, Wu SG (2013) Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies. Eur J Med Chem 65:112鈥?18PubMed View Article
作者单位:Lianbao Ye (1) Jie Wu (1) Jiebo Yang (2) Weiqiang Chen (2) Yan Luo (1) Yanmei Zhang (1)
1. Medicinal Chemistry Department, Guangzhou Higher Education Mega Center, Guangdong Pharmaceutical University, No. 280, Wai Huan Dong Road, Guangzhou, 510006, Guangdong, China 2. School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, China